Incidence of Lobar and Non-Lobar Spontaneous Intracerebral Haemorrhage in a Predominantly Hispanic-Mestizo Population – The PISCIS Stroke Project: A Community-Based Prospective Study in Iquique, Chile
Artículo
Open/ Download
Publication date
2010Metadata
Show full item record
Cómo citar
Lavados Germain, Pablo Manuel
Cómo citar
Incidence of Lobar and Non-Lobar Spontaneous Intracerebral Haemorrhage in a Predominantly Hispanic-Mestizo Population – The PISCIS Stroke Project: A Community-Based Prospective Study in Iquique, Chile
Author
Abstract
Background: The incidence of intracerebral haemorrhage
(ICH) in Hispanics is high, especially of non-lobar ICH. Our
aim was to ascertain prospectively the incidence of first-ever
spontaneous ICH (SICH) stratified by localisation in a Hispanic-
Mestizo population of the north of Chile. Methods: Between
July 2000 and June 2002 all possible cases of ICH were
ascertained from multiple overlapping sources. The cases
were allocated according to localisation. Those with vascular
malformations or non-identifiable localisations were excluded.
Results: We identified a total of 69 cases of first-ever ICH. Of these, 64 (92.7%) had SICH, of which we allocated 58 cases
(84%) to non-lobar or lobar localisation. The mean age
was 57.3 8 17 years, and 62.3% of the subjects were male.
The age-adjusted incidence rates were 13.8 (non-lobar) and
4.9 (lobar) per 100,000 person-years. Non-lobar SICH was
more frequent in young males and lobar SICH in older women.
The non-lobar-to-lobar ratio was similar to previous findings
in Hispanics. Hypertension was more frequent in nonlobar
SICH and in diabetes, heavy drinking and antithrombotic
use in lobar SICH, but in none significantly. There was
no association between localisation and prognosis. Conclusions:
The incidence of non-lobar SICH was high, but lower
than in most non-white populations. This lower incidence
could be due to a lower population prevalence of risk factors,
a higher socioeconomic level in this population, or chance.
Patrocinador
P.M.L. has received research grants, research support and
travel grants by Sanofi-Synthelabo Chile, Boehringer Ingelheim
and Glaxo Smith Kline. C.S. has received research support and
travel grants by Sanofi-Synthelabo Chile, Boehringer Ingelheim
and Glaxo Smith Kline.
This investigation was possible thanks to the unconditional
support of Sanofi-Aventis Chile, Glaxo Smith Kline and Boehringer
Ingelheim.
Quote Item
Neuroepidemiology 2010;34:214–221
Collections